To investigate the clinical aspects of CHT in atopic dermatitis (AD) treatments, the effect of CHT in anti-oxidative and anti-inflammatory cytokines were tested. 100% or higher cell viability was observed in all tested groups from 25 to 200 ${mu}g/m{ell}$ using Raw 264.7 cells. CHT showed dose-dependent DPPH scavenging activity, with more than 90% scavenging activities at 800 ${mu}g/m{ell}$ concentrations. CHT showed dose-dependent suppression activity of ROS production, especially at 200 ${mu}g/m{ell}$ of 37.5%. CHT decreased NO production activity, with significant decrease of 33.2% at 200 ${mu}g/m{ell}$. IL-6, MCP-1, TNF-${alpha}$ production rate were decreased by approximately 25% when Raw 264.7 cells were treated with LPS and with CHT of 200 ${mu}g/m{ell}$. Also, IL-$1{eta}$ production rate was decreased by 25% at 100 ${mu}g/m{ell}$. The results above indicate that CHT significantly reduces the effect of oxidative and inflammatory cytokines. The use of CHT in dermatitis can be widely suggested.